Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News New study shows promise of targeted ovarian cancer therapy

New study shows promise of targeted ovarian cancer therapy

5th June 2017

A promising new targeted approach to treating ovarian cancer has shown encouraging results in an early clinical trial.

The Institute of Cancer Research in London and the Royal Marsden NHS Foundation Trust carried out a test of a new drug called ONX-0801 in 15 women with ovarian cancer, as part of a wider phase I clinical trial.

ONX-0801 was shown to significantly shrink tumours in seven of the 15 patients; moreover, participants whose tumours included the particular molecular target for the drug saw an even higher success rate, with seven of ten women responding.

This is the first in a new class of drugs that attacks ovarian cancer by mimicking folic acid to enter cancer cells, allowing it to block a molecule called thymidylate synthase and cause irreparable DNA damage.

Because it is specifically targeted, the drug has none of the side effects often seen with traditional chemotherapy, such as infections, diarrhoea, nerve damage and hair loss.

Dr Udai Banerji, deputy director of the drug development unit at the Institute of Cancer Research, said: "The results we have seen in this trial are very promising. It is rare to see such clear evidence of reproducible responses in these early stages of drug development."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801836549-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.